Compare
Anbio Biotechnology vs Aspira Women's Health Inc. vs Biomerica Inc vs Insight Molecular Diagnostics Inc.
| Latest fiscal year | Anbio Biotechnology NNNN | Aspira Women's Health Inc. AWHL | Biomerica Inc BMRA | Insight Molecular Diagnostics Inc. IMDX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-05-31 | 2025-12-31 |
| Revenue | $8.65M | $9.22M | $4.45M | $4.05M |
| Revenue growth (YoY) | +5.6% | +0.4% | -16.2% | +115.6% |
| Gross margin | 87.2% | 64.2% | 8.1% | 56.7% |
| Operating margin | 66.7% | -85.9% | -119.5% | n/m |
| Net margin | 74.1% | -138.7% | -84.8% | n/m |
| Net income | $6.40M | -$12.78M | -$3.77M | -$50.22M |
| EPS (Diluted) | $0.15 | -$0.37 | -$1.30 | -$1.65 |
| Operating cash flow | -$6.74M | -$7.03M | -$3.42M | -$22.18M |
| Free cash flow | n/a | -$7.04M | n/a | -$25.37M |
| Cash & equivalents | $7.77M | $1.75M | $1.31M | $11.58M |
| Total assets | $30.24M | $5.46M | $6.76M | $25.76M |
| Total liabilities | $87.8K | $12.39M | $4.13M | $57.22M |
| Shareholders' equity | $30.16M | -$6.93M | $2.63M | -$31.46M |
| Return on year-end equity | 21.2% | n/a | -143.5% | n/a |
| Shares outstanding | n/a | 43.48M | 3.20M | 28.68M |
Revenue, most recent five fiscal years
| Fiscal year | Anbio Biotechnology | Aspira Women's Health Inc. | Biomerica Inc | Insight Molecular Diagnostics Inc. |
|---|---|---|---|---|
| Latest | $8.65M Ended 2025-12-31 | $9.22M Ended 2025-12-31 | $4.45M Ended 2026-05-31 | $4.05M Ended 2025-12-31 |
| 1 year earlier | $8.19M Ended 2024-12-31 | $9.18M Ended 2024-12-31 | $5.31M Ended 2025-05-31 | $1.88M Ended 2024-12-31 |
| 2 years earlier | $6.71M Ended 2023-12-31 | $9.15M Ended 2023-12-31 | $5.42M Ended 2024-05-31 | $1.50M Ended 2023-12-31 |
| 3 years earlier | $23.54M Ended 2022-12-31 | n/a | $5.34M Ended 2023-05-31 | $958.0K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $18.87M Ended 2022-05-31 | $2.20M Ended 2021-12-31 |